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Abstract
Background: Patients with pathogenic variants in ZBTB18 present with Intellectual
Disability (ID) with frequent co-occurrence of corpus callosum (CC) anomalies,
hypotonia, microcephaly, growth problems and variable facial dysmorphologies.
These features illustrate a key role for ZBTB18 in brain development.
Methods: Patients with a pathogenic variant in ZBTB18 were detected by diag-
nostic whole exome sequencing (WES) performed in our center. We reviewed the
literature and used GeneMatcher to include other cases. YASARA and WHAT IF
were used to provide insight into the structural effect of missense variants located
in the C2H2 zinc finger domains of the ZBTB18 protein.
Results: We give a complete overview of pathogenic variants in ZBTB18
detected to date, showing inconsistent presence of clinical features, including CC
anomalies. We present four new cases with a de novo pathogenic variant in the
ZBTB18 gene, including the fourth case in which a de novo p.Arg464His variant
was found.
Conclusion: Homology modeling of protein structure points to a variable degree
of impaired DNA binding caused by missense variants in these domains probably
leading to Loss of Function (LoF). Putative partial LoF may present with a less
distinctive phenotype than complete LoF, as seen in truncating variants, which
presents with an extensive variability in the phenotypic spectrum. Our data do not
support a clear genotype to phenotype correlation.
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1 | INTRODUCTION
Patients with a 1q43q44 microdeletion (OMIM# 612337)
present with variable intellectual disability (ID), possible
agenesis of the corpus callosum (ACC) and variable micro-
cephaly. The ZBTB18 gene (ZNF238; OMIM# 608433) has
previously been identified as contributing factor for the
1q43q44 deletion syndrome phenotype. Some of the
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features seen, such as CC anomalies have been linked to
haploinsufficiency of the ZBTB18 gene (Ballif et al.,
2012). Seizures seen in some cases with a 1q43q44 dele-
tion are explained by loss of the HNRNPU (OMIM#
602869) gene (Depienne et al., 2017; Hamdan et al., 2014;
Hemming et al., 2016; de Kovel et al., 2016). Dysmorphic
facial features (e.g., hypertelorism, strabismus, prominent
nasal tip, bulbous nose, abnormal philtrum or lips, micro-
or retrognathia, abnormal ears) and other clinical features,
such as growth problems are inconsistently described in
these patients and have not been linked to a specific gene
in the 1q43q44 region yet.
Patients with a pathogenic variant in the ZBTB18 gene
show phenotypic overlap with 1q43q44 microdeletion syn-
drome patients. Multiple case reports and patient series have
been published to delineate the clinical phenotype of the
ZBTB18- related disorder (Cohen et al., 2017; Depienne
et al., 2017; de Munnik et al., 2014). In approximately half
of the described cases, CC anomalies, hypotonia, micro-
cephaly, growth problems and variable facial dysmorpholo-
gies were reported as well (Cohen et al., 2017). Presumably,
pathogenic variants in ZBTB18 cause variable CC anomalies
with a reduced penetrance (Depienne et al., 2017).
The aim of this study was to further delineate pheno-
typic spectrum of patients with de novo ZBTB18 variants,
to establish a putative genotype-phenotype correlation and
to characterize the putative molecular effect of ZBTB18
missense variants on protein function, using homology-
based-modeling. We present four new cases with a de novo
pathogenic variant in the ZBTB18 gene and review 21
previously described cases.
2 | MATERIALS AND METHODS
2.1 | Ethical compliance
Written informed consent of the patients’ parents was
obtained before inclusion in the exome- sequencing study/
diagnostic exome sequencing. This study was approved by
the local institutes under the realm of routine diagnostic
genetic testing. Patients’ parents were counseled by a clini-
cal geneticist and gave written informed consent for the
diagnostic procedure. As a result, these patients or their
families were not subjected to additional investigations for
the purposes of research. No formal ethical board review
was required for this retrospective research/patient file
research type of study, since data are already available
from routine diagnostic testing.
2.2 | Exome sequencing
Routine diagnostic whole exome sequencing (WES) in
patients with ID from the University Medical centers in
Maastricht and Nijmegen identified three patients with a de
novo variant in the ZBTB18 gene. Written informed con-
sent was obtained from patients’ parents for exome
sequencing and written permission was obtained for inclu-
sion of clinical photographs (where applicable).
The WES procedure was performed, using the previ-
ously described trio parent-offspring approach (Veltman &
Brunner, 2012). DNA was isolated from blood according
to standard procedures. Exome capturing was performed,
using the Agilent SureSelect v4 kit (Agilent, Santa Clara,
CA, USA) and exome libraries sequencing was performed,
using an Illumina HiSeq instrument (Illumina, San Diego,
CA, USA) with 101 bp paired-end reads at a median cov-
erage of 759. BWA version 0.5.9-r16 was used to align
sequence reads to the hg19 reference after which the
GATK unified genotyper, version 3.2-2 was used to call
variants, combined with annotation, using a custom diag-
nostic annotation pipeline. Calling of de novo variants in
index patients was performed according to de Ligt et al.
(2012). To validate these de novo variants, standard Sanger
sequencing was performed on patients and parental DNA.
Using genematcher (https://genematcher.org; Sobreira,
Schiettecatte, Valle, & Hamosh, 2015) we identified a fifth
patient with a de novo ZBTB18 variant. Literature was
reviewed to include patients previously described.
2.3 | Molecular modeling of ZBTB18
missense variants
To obtain insight into the putative effect of the missense
variants on the molecular structure of the ZBTB18 protein,
a homology model was created. We used the extensively
validated YASARA (Krieger, Koraimann, & Vriend, 2002)
and WHAT IF twinset homology scripts (Vriend, 1990).
Since no crystal structure of ZBTB18 is available, PDB file
5K17 was used to create a homology model for amino acid
residues 430–500, which are ~40% identical to the homo-
logue. The effect of the missense variants on ZBTB18 pro-
tein structure was analyzed using standard biochemical
amino acid characteristics (i.e., chemical structure and size,
polarity of the side chain, charge, and isoelectric point) and
knowledge from the Uniprot database (The UniProt Con-
sortium, 2017). Variants were identified by comparison
with the NCBI reference protein sequence NP_991331.1
encoded by transcript NM_205768.2 (www.ncbi.nlm.nih.
gov/gene) and described according to HGVS guidelines.
3 | RESULTS
3.1 | Clinical data and variants in ZBTB18
We present four new cases with a de novo ZBTB18 variant.
Patient 1, a 15-year-old boy, presented with developmental
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delay, hypotonia, and seizures. His head circumference
(OFC) was 52 cm (2.25SD). His height was 160 cm
(2SD). MRI did not reveal corpus callosum abnormali-
ties, nor other structural brain anomalies. He had a promi-
nent and bulbous nose and showed strabismus. He carried
a de novo missense variant Chr1(GRCh37):g.24421
8415T>C, NM_205768.2(ZBTB18):c.1339T>C (p.(Tyr447-
His)). This variant is predicted to be probably damaging
(Polyphen score 0.969) and deleterious (SIFT score 0) and
affects a conserved amino acid residue (conserved up to
fish) located in a C2H2 zinc finger (ZNF) domain of the
ZBTB18 protein. This variant has not been described in
individuals from the ExAC database (exac.broadinstitute.
org).
Patient 2, a 1-year-old boy, presented with microcephaly
(OFC 43.5 cm; 2.8 SD) and attacks of abnormal arm
extension. His motor and speech development were
delayed. He showed truncal hypotonia on physical exami-
nation. His length was 84 cm, he weighed 10 kg. EEG
results were normal. MRI showed a short and hypoplastic
corpus callosum of which the splenium was affected more
than the rostrum (Figure 1). He had an upward slant, a
small and somewhat sloping forehead, depressed nasal
bridge, small and upturned nose tip and nostrils, elongated
philtrum and a thin upper lip. A de novo nonsense variant
was found: Chr1(GRCh37):g.244217655G>A, NM_205
768.2(ZBTB18): c.579G>A (p.(Trp193*)) that leads to a
premature stop codon.
Patient 3, a 13-year-old boy, presented with mild to
moderate speech and developmental delay and attention
deficit disorder (ADD). He did not have hypotonia. His
OFC was 52.5 cm (1.25 SD). He was 156 cm tall
(0.75 SD). No structural brain anomalies were seen on
MRI. He had retrognathia, mild hypertelorism, and a
slightly elongated philtrum and thin upper lip. His hands
were broad and short. Mild syndactyly of the second and
third toe with a sandal gap were seen in both feet. WES
analyses showed a de novo frameshift variant Chr1
(GRCh37):g.244217335del, NM_205768.2(ZBTB18):c.259
del(p.(Leu87Cysfs*21)), that leads to a premature termina-
tion codon located more than 400 codons upstream of the
canonical termination codon.
Patient 4, a 4-year-old boy, presented with severe
speech delay, motor delay, and hypotonia. MRI showed
agenesis of the splenium of the corpus callosum. At
3 years of age, an OFC of 49 cm was measured (1 SD).
His height was 98 cm (0 SD). He had hypertelorism, a
prominent nasal tip, and a bulbous nose, a small mouth
and retro- and micrognathia. His fingers showed broad tips.
He carried a missense variant in ZBTB18 (Chr1(GRCh37):
g.244218467G>A, NM_205768.2(ZBTB18):c.1391G>A(p.
Arg464His)). This heterozygous de novo missense variant
is predicted to be deleterious (SIFT score 0; Polyphen
score 0.991) and affects a highly conserved amino acid
residue located in the ZNF domain of the ZBTB18 protein
(conserved up to Tetraodon). This variant has not been
found in individuals from the ExAC database.
We reviewed four patient cohorts containing one or
more patients with pathogenic variants in ZBTB18 (Cohen
et al., 2017; Depienne et al., 2017; Lopes et al., 2016;
Rauch et al., 2012) and included one case report (de Mun-
nik et al., 2014). So far, a total of 25 patients with a patho-
genic ZBTB18 variant have been reported in literature and
in this study. All patients presented with developmental
delay in varying degrees with prominent speech delay. Fif-
teen patients underwent an MRI scan. Nine of them
showed corpus callosum abnormalities. Results of clinical
evaluation of congenital anomalies in 13 patients were pre-
sent: dysmorphic facial features were seen in 10 patients,
epilepsy was described in five patients, hypotonia in seven,
FIGURE 1 Midsagittal MRI images. Left: Patient 1. One-year-old boy with corpus callosum dysgenesis. T1-FLAIR. Width I:
II = 1:3.6. Right: Normal control. Two-year-old boy. T2-FLAIR. Width I:II = 1:2.2. Case courtesy of Dr Bruno Di Muzio,
Radiopaedia.org
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and dystonia in two. Data about growth, development, neu-
rological, or congenital anomalies was incomplete in 13
cases. Clinical data of cases included in this study
and patients from literature are presented in Table 1. Vari-
ants in the ZBTB18 gene are schematically depicted in
Figure 2.
3.2 | Homology modeling and analysis of
ZBTB18 missense variants
Variants in the ZNF domain of ZBTB18 were studied,
using a homology model of this domain. The recurrent
de novo p.(Arg464His) variant within the C2H2 ZNF
domain of ZBTB18 may impair DNA-binding properties
of ZBTB18. In the wild-type protein, the Arg464
residue is directed towards the major groove of the
DNA and probably required for specific interactions
between the transcription factor and the DNA. The sub-
stitution of this residue for a smaller and neutrally
charged histidine might affect these interactions and
thereby change the binding of the protein to its target
DNA sequence (Figure 3 - left).
The p.(Tyr447His) variant carried by patient 1 will
affect tyrosine 447, which is pointed towards the phos-
phate backbone of the DNA. The possible hydrogen
bonds between Y447 and the DNA will be lost because
histidine is a smaller residue that will not be able to
make the same interactions. This variant is therefore
likely to affect the interaction between DNA and protein
(Figure 3 - right).
TABLE 1 Clinical characterization of patients carrying a pathogenic variant in ZBTB18 (ref. transcript NM_205768.2) described so far
Patient nr.
(corresponding
Figure 3)
This study Cohen et al., 2017
1 2 3 4 5 6 7 8 9 10 11 12
p.(Tyr-
447His)
p.(Trp-
193*)
p.(Leu-
87Cysfs*21)
p.(Arg-
464His)
p.(Gln-
486Glu)
p.(Ala-
186Pro)
p.(Ans-
461Ser)
p.(Arg-
315Glyfs*4)
p.(Gln-
395*)
p.(Arg-
464His)
p.(Arg-
45*)
p.(Arg-
495Cys)
Sex M M M M F F M M M M M F
Age at
examination
(years)
15.0 1.0 13.0 4.0 U U 7.0 3.0 4.0 34.0 6.0 18.0
Growth at examination (Hall, Allanson, Gripp, & Slavotinek, 2007)
Height (cm) 160.0 84.0 156.0 98.0 U U 136.0 90.5 98.0 178.0 122.0 169.0
Height (SD) 1.0 1.0 0.0 1.5 U N 2.0 1.0 1.0 0.0 1.0 0.0
Weight (kg) 47.5 10.0 40.0 15.0 U U 23.9 12.7 13.2 N 20.6 57.0
Weight (SD) 0.5 1.0 1.0 1.3 U U 0.0 1.0 0.0 0.0 0.0 1.0
OFC (cm) 52.0 43.5 52.5 49.0 U U 50.5 47.5 47.2 58.0 50.0 U
OFC (SD) 2.0 2.8 1.0 1.8 U <2 1.0 1.0 2.0 1.0 1.0 U
Development
Cognitive
delay
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
Motor delay U Yes U U U Yes Yes Yes Yes Yes No Yes
Speech delay Yes Yes Yes Yes U Yes Yes Yes Yes Yes Yes Yes
Neurology
Corpus
callosum
abnormalities
No Yes No Yes U No Yes Yes Yes U Yes No
Hypotonia Yes No No Yes U No Yes Yes Yes No Yes No
Seizures Yes No No No U No No No No** No Yes No
Behavioural No No Yes No U U Yes U U U Yes U
Other No Yes No No U Yes Yes No Yes No No No
Congenital anomalies
Facial features Yes Yes Yes Yes U U No Yes Yes Yes Yes No
Cardiac No No No No U U No No No No No No
Urogenital No No No No U U Yes No No No No No
Gastrointestinal No No No No U U No No No No No No
Other No No Yes Yes U U Yes No Yes No No No
N, Normal; U, Unknown.
*Number of patients for which clinical characteristics are known.
**Febrile seizures. OFC ≤ 2 SD (e.g. microcephalic) and Corpus Callosum Abnormalities ‘Yes’ (e.g. present) highlighted in bold.
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4 | DISCUSSION
In this study, we confirm pathogenic variants in ZBTB18
have major clinical consequences with an extensive and
highly variable phenotypic impact. This is the most exten-
sive review of clinical phenotypic features in patients with
ZBTB18 pathogenic variants to date and the first study to
investigate the genotype-phenotype correlation of LoF vs
missense variants.
With ACC not being consistently present, we hypothe-
size that variants in ZBTB18 are likely to cause a spectrum
of structural corpus callosum abnormalities, that is, partial
or global hypoplasia or agenesis in varying degrees. Other
major features seen were developmental delay, dysmorphic
facial features, and hypotonia.
Our data show no strong causal relation between
ZBTB18 pathogenic variants and seizures as this feature
was present in only four out of 17 patients for whom sei-
zure history information was available. This suggests that
deletion of the HNRNPU gene is indeed an important con-
tributor to this feature in patients with 1q43-44 deletions
(Hamdan et al., 2014; de Kovel et al., 2016; Depienne
et al., 2017). Still, epilepsy is a feature of the ZBTB18-
related genetic disorder and a role for ZBTB18 haploinsuffi-
ciency in epileptogenesis can therefore not be definitely
excluded based on our data.
We explored a possible genotype-phenotype correlation
by the two putative mechanisms by which LoF (nonsense
or frameshift) variants and missense variants cause alter-
ations in the DNA-binding capacity of ZBTB18. We did
Depienne et al., 2017
Total*
13 14 15 16 17 18 19 20 21 22 23 24 25
p.(Glu-
133*)
p.(Arg-
195*)
p.(Gly-
208*)
p.(Pro-
212Hisfs*10)
p.(Gln-
271*)
p.(Glu-
350Argfs*15)
p.(Arg-
464His)
p.(Ser-
373Thrfs*26)
p.(Cys-
54Arg)
p.(His-
15Arg)
p.(Arg-
464His)
p.(Leu-
434Pro)
p.(Ser-
200*)
F F M F M M F M U M F M F
2.0 5.0 U U U U U 15.0 U 14.0 12.0 23.0 12.0
7/17
79.0 U U U U U U U U 172.0 142.0 192.0 155.5 Microcephaly
<2 N U U U U U N U 1.0 1.8 3.0 1.0
43.0 U U U U U U U U 44.0 29.5 U 54.9
<2 N U U U U U N U 0.3 1.5 U 2.0
U U U U U U U U U 54.5 50.0 54.5 54.0
U <2 U U U U U N <2 0.0 2.3 1.0 0.5
25/25
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Devel. delay
Yes Yes Yes Yes Yes Yes Yes U U Yes Yes Yes Yes
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
9/15
No No U U U U U U U Yes Yes U Yes Corpuscallosum
abnormalities
No No U U U U U U U Yes No No No
No No U U U U U U U No No Yes Yes
U Yes U U U U U U U U Yes U Yes
No Yes U U U U U U U Yes No U No
10/13
Yes No U U U U U No Yes U U U U Facial features
No No U U U U U No U U U U U
No No U U U U U No U U U U U
No No U U U U U No U U U U U
Yes Yes U U U U U U U U U U U
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not find a clear genotype-phenotype correlation with regard
to position of the variant or type of the variant (i.e., LoF
vs. missense).
ZBTB18 has a key role in cortical development, which
probably explains the ID seen in patients carrying a patho-
genic variant in this gene (Cohen et al., 2017). ZBTB18
functions as a transcriptional repressor influencing neu-
ronal growth, differentiation, and maturation (Baubet
et al., 2012; Ohtaka-Maruyama et al., 2013; Okado et al.,
2009). It represses PAX6 (OMIM# 607108), NEUROG2
(OMIM# 606624) and NEUROD1 (OMIM# 601724).
Expression of these three sequential proneurogenic genes
causes intermediate neurogenic progenitors (INP) to differ-
entiate and migrate. Importance of time- and place-specific
expression is hypothesized (Xiang et al., 2012). Loss of
function of ZBTB18-driven gene control could lead to
early loss of transcriptional repression. Consequently, a
premature differentiation and migration of INP’s in this
area, with subsequent disturbed neuronal development is
to be expected.
ZBTB18 shows strong evolutionary conservation. For
example, the overall human protein identity is 78% with
Danio rerio and 99.4% with M. musculus, with even higher
identity in the C2H2 ZNF domains. The protein is pre-
dicted to be highly intolerant to loss-of-function (LoF) vari-
ants, as is evident from the absence of LoF variants in
ExAC and a high probability of loss-of-function Intolerance
(pLI) of 0.97 (exac.broadinstitute.org; Lek et al. 2016) and
a high-rank haploinsufficiency score of 8.37 (Ni Huang,
Lee, Marcotte, & Hurles, 2010).
Nonsense and frameshift variants lead to a premature
termination codon in the last (second) exon of the ZBTB18
gene (Kuzmiak & Maquat, 2006). Nonsense-mediated
decay (NMD) of ZBTB18 mRNA is not expected to occur
for these variants and they will probably lead to truncated
proteins without the C2H2 ZNF domain. The eight
FIGURE 2 Pathogenic variants in ZBTB18 (ref. transcript NM_205768.2) with Zn fingers (1–4) in exon 2. Numbers corresponding with
Table 1. (A) Rauch et al., 2012; (B) Lopes et al., 2016; (C) Cohen et al., 2017; (D) Depienne et al., 2017
FIGURE 3 Close-up of the recurrent de novo pathogenic variant Arg464His (left) and the pathogenic variant Tyr447His (right). The protein
is colored gray, the side chains of both wild-type and the mutant residue are shown and colored green and red, respectively
398 | VAN DER SCHOOT ET AL.
nonsense and three out of five frameshift variants, we
report are situated before or in Znf1. These pathogenic
variants cause loss of DNA-binding domains and the
expected truncated proteins are likely to be dysfunctional.
Subsequent haploinsufficiency is therefore most likely the
cause of the observed phenotypic spectrum in patients with
nonsense or frameshift variants in ZBTB18. We suggest
this to be a more plausible explanation than a theoretical
dominant negative effect or gain of function of the trun-
cated protein, in particular given the high-rank pLI and
haploinsufficiency scores mentioned above.
By homology modeling, we illustrated a possible alter-
ation in function caused by missense variants. ZBTB18
encodes for a protein with four C2H2 Zinc fingers, struc-
tures found in nearly half of DNA-binding factors and
known to be involved in numerous biological processes
(Persikov et al., 2015). Our homology model shows how
the recurrent p.Arg464His substituting variant in the C2H2
structure of ZNF 3 probably affects DNA-binding proper-
ties. Impaired binding of ZBTB18 to DNA will disturb its
function as transcriptional repressor. This could lead to an
increase in transcription of ZBTB18 target genes, similar to
LoF-based haploinsufficiency caused by truncating variants.
Of the four patients identified thus far with the recurrent de
novo p.Arg464His variant, two showed corpus callosum
abnormalities while the other two did not undergo MRI
imaging. A third patient (Cohen et al., 2017) with a struc-
tural anomaly of the corpus callosum carried a missense
variant in the ZNF3 domain. The homology model of
another (missense) variation (p.Tyr447His) in the zinc finger
domains proved to cause a less distinctive change compared
to the wildtype, coherent with a less pronounced phenotype.
We note that a very similar distribution of variants was
recently documented for the YY1 gene (OMIM# 600013),
which also encodes for a transcription factor with four
C2H2-type zinc fingers. Strikingly, the missense variants in
the YY1 gene that cause intellectual disability, also appear
to cluster in the zinc finger domains, with different variants
affecting the identical amino acid residue (Gabriele et al.,
2017). Mutational clustering in the ZNF region is described
for ZBTB20 (OMIM# 606025) as well, where de novo vari-
ants in the C2H2 ZNF domain of this protein lead to a
hypothyroidism phenotype (Mattioli et al., 2016). In
ZBTB42 (OMIM# 613915), a p.Arg>His in one of its
C2H2 ZNF domains causes a lethal congenital contracture
syndrome (Patel et al., 2014). Liu et al. (2016) described
functional characterization of variants in the ZNF region of
ZBTB7A (OMIM# 605878) and invariably demonstrated
loss of function. We expect clustering of missense variants
in the C2H2 regions of other genes with homologous pro-
tein domains (Wiel, Venselaar, Veltman, Vriend, & Gilis-
sen, 2017), causing phenotypic features by disabling proper
DNA binding as well.
In conclusion, our data contribute to further delineate
the heterogeneous phenotype of the ZBTB18-related disor-
der. Homology modeling points to a variable degree of
LoF caused by missense variants in C2H2 domains of
ZBTB18. A lesser degree of LoF will present with a less
distinctive phenotype. Complete LoF however, as can be
seen in truncating variants, will present with an extensive
variable phenotypic spectrum in which we could not define
a clear genotype to phenotype presentation.
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